企業プロフィール
GSK plc 株価・ニュース・カタリスト
- ティッカー:
- GSK
- 取引所:
- NYSE
- セクター:
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- 所在地:
- United Kingdom and listed in the U
株価パフォーマンス
50.28 USD (+1.53%)
終値
最終更新: 2026年8月17日
98.3B USD
時価総額
株価変動の要因
As of Aug 17, 2026, GSK closed up 1.53% at $50.28. No new same-company headline was identified in the current news window.
企業概要
Global Biopharmaceutical Portfolio
GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced assets.
Specialty Medicines
Specialty Medicines are a primary growth engine for GSK. HIV therapies, oncology products, and respiratory and immunology medicines give the company a broad commercial presence across chronic and specialty-care markets.
Vaccines Franchise
GSK maintains one of the industry’s major vaccine portfolios. Shingrix, meningococcal vaccines, Arexvy, and other established products provide a large commercial base supported by global immunization infrastructure.
Expanding Late-Stage Pipeline
Recent development activity includes the acquisition of the late-stage non-small cell lung cancer assets Jideytro and neladalkib, regulatory-supporting data for Jemperli in locally advanced rectal cancer, and pivotal evidence for bepirovirsen as a potential functional cure for chronic hepatitis B.
External Innovation Strategy
GSK supplements internal research through acquisitions, licensing, and partnerships that add differentiated late-stage assets. The addition of Jideytro and neladalkib illustrates the company’s use of business development to strengthen therapeutic areas where it already has commercial and clinical infrastructure.
今後のカタリスト
- A regulatory decision for neladalkib in non-small cell lung cancer is expected in the second half of 2026.
- Regulatory progress for the Jemperli label expansion in locally advanced rectal cancer will be supported by results from the AZUR-1 study.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。